MARCH8 inhibits viral infection by two different mechanisms.
HIV-1
MARCH8
antiviral factor
envelope
human
infectious disease
microbiology
tyrosine motif
ubiquitination
virus
Journal
eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614
Informations de publication
Date de publication:
11 08 2020
11 08 2020
Historique:
received:
10
04
2020
accepted:
30
07
2020
entrez:
12
8
2020
pubmed:
12
8
2020
medline:
13
2
2021
Statut:
epublish
Résumé
Membrane-associated RING-CH 8 (MARCH8) inhibits infection with both HIV-1 and vesicular stomatitis virus G-glycoprotein (VSV-G)-pseudotyped viruses by reducing virion incorporation of envelope glycoproteins. The molecular mechanisms by which MARCH8 targets envelope glycoproteins remain unknown. Here, we show two different mechanisms by which MARCH8 inhibits viral infection. Viruses pseudotyped with the VSV-G mutant, in which cytoplasmic lysine residues were mutated, were insensitive to the inhibitory effect of MARCH8, whereas those with a similar lysine mutant of HIV-1 Env remained sensitive to it. Indeed, the wild-type VSV-G, but not its lysine mutant, was ubiquitinated by MARCH8. Furthermore, the MARCH8 mutant, which had a disrupted cytoplasmic tyrosine motif that is critical for intracellular protein sorting, did not inhibit HIV-1 Env-mediated infection, while it still impaired infection by VSV-G-pseudotyped viruses. Overall, we conclude that MARCH8 reduces viral infectivity by downregulating envelope glycoproteins through two different mechanisms mediated by a ubiquitination-dependent or tyrosine motif-dependent pathway.
Identifiants
pubmed: 32778221
doi: 10.7554/eLife.57763
pii: 57763
pmc: PMC7419139
doi:
pii:
Substances chimiques
Viral Envelope Proteins
0
MARCHF8 protein, human
EC 2.3.2.27
Ubiquitin-Protein Ligases
EC 2.3.2.27
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Japan Society for the Promotion of Science
ID : 18K07156
Pays : International
Informations de copyright
© 2020, Zhang et al.
Déclaration de conflit d'intérêts
YZ, TT, SO, SK, HF, KT No competing interests declared
Références
J Virol. 2003 Oct;77(19):10645-50
pubmed: 12970449
J Biol Chem. 2013 Mar 1;288(9):6617-28
pubmed: 23300075
J Lab Clin Med. 1950 Nov;36(5):754-8
pubmed: 14784641
J Biol Chem. 2009 Dec 11;284(50):35060-72
pubmed: 19837671
PLoS One. 2010 Dec 02;5(12):e15132
pubmed: 21151997
J Virol. 2004 Feb;78(3):1109-20
pubmed: 14722266
Nat Med. 2015 Dec;21(12):1502-7
pubmed: 26523972
J Immunol. 2006 Jul 1;177(1):341-54
pubmed: 16785530
J Biol Chem. 2007 Aug 24;282(34):24806-15
pubmed: 17604280
J Exp Med. 2011 Jan 17;208(1):149-65
pubmed: 21220452
J Virol. 1988 Jun;62(6):2107-14
pubmed: 2452899
Mol Biol Cell. 2011 Sep;22(17):3218-30
pubmed: 21757542
J Biol Chem. 2019 Mar 8;294(10):3397-3405
pubmed: 30630952
J Biol Chem. 2003 Apr 25;278(17):14657-68
pubmed: 12582153
J Cell Sci. 2013 Jul 1;126(Pt 13):2798-809
pubmed: 23606747
Proc Natl Acad Sci U S A. 2012 Aug 28;109(35):14128-33
pubmed: 22904187
J Virol. 1986 Aug;59(2):284-91
pubmed: 3016298
AIDS Res Hum Retroviruses. 1999 Sep 20;15(14):1321-4
pubmed: 10505681